Provided by Tiger Trade Technology Pte. Ltd.

Foghorn Therapeutics Inc.

1.99
-0.1000-4.78%
Volume:1.23M
Turnover:2.42M
Market Cap:118.18M
PE:-2.04
High:2.14
Open:2.05
Low:1.89
Close:2.09
52wk High:7.61
52wk Low:1.79
Shares:59.39M
Float Shares:25.58M
Volume Ratio:0.33
T/O Rate:4.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9742
EPS(LYR):-1.1800
ROE:-470.38%
ROA:-19.92%
PB:-1.46
PE(LYR):-1.69

Loading ...

Foghorn Therapeutics - Estimates $2.30 Mln Charges for Workforce Reduction in Q4 2026 - SEC Filing

THOMSON REUTERS
·
Oct 01

Foghorn Therapeutics Inc.: One-Time Employee Severance and Benefit Costs That are Expected to be Incurred in Q4 of 2026

THOMSON REUTERS
·
Oct 01

Foghorn Therapeutics: Also not be Advancing Selective Smarca2 Degrader Program, Companies Do not Anticipate Further Collaboration Activities

THOMSON REUTERS
·
Oct 01

Foghorn Therapeutics - to Focus Resources on Wholly Owned Pipeline Including Ep300 and Cbp Degraders

THOMSON REUTERS
·
Oct 01

Foghorn Therapeutics - Expects Cash Runway into Second Half of 2029 with 40% Workforce Reduction

THOMSON REUTERS
·
Oct 01

Foghorn Therapeutics Provides Update on Fhd-909 and Strategic Priorities

THOMSON REUTERS
·
Oct 01

Foghorn Therapeutics - to Reduce Workforce by About 40% and Align Operating Structure

THOMSON REUTERS
·
Oct 01

Foghorn Therapeutics - Co and Lilly Will not Advance Fhd-909 or Selective Smarca2 Degrader Program

THOMSON REUTERS
·
Oct 01

Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities

GlobeNewswire
·
Oct 01

NASDAQ Trade Halt Halt News Pending at 06:55 Am

Reuters
·
Oct 01

Evercore ISI Reaffirms Their Buy Rating on Foghorn Therapeutics (FHTX)

TIPRANKS
·
Aug 10

Foghorn Therapeutics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Foghorn Therapeutics Reports Q2 Results and Pipeline Progress

TIPRANKS
·
Aug 06

Foghorn Therapeutics Q2 EPS $(0.10) Beats $(0.23) Estimate, Sales $16.072M Beat $5.995M Estimate

Benzinga Earnings
·
Aug 06

Foghorn Therapeutics Q2 FY26 Net Loss Narrows to $7.2 Million; Collaboration Revenue Rises to $16.1 Million

Reuters
·
Aug 06

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

THOMSON REUTERS
·
Aug 06

Foghorn Therapeutics Inc Expected to Post a Loss of 26 Cents a Share - Earnings Preview

Reuters
·
Jul 31

Analysts’ Top Healthcare Picks: Lemaitre Vascular (LMAT), Foghorn Therapeutics (FHTX)

TIPRANKS
·
Jul 20

Foghorn Therapeutics Shareholders Elect Directors at Annual Meeting

Reuters
·
Jun 25

Foghorn Therapeutics to present at Goldman Sachs Global Healthcare Conference 2026

Reuters
·
Jun 05